MaronBJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med2018; 379: 1977.
2.
OmmenSRMitalSBurkeMA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation2020; 142: e533–e557.
3.
NagSTrivediDVSarkarSS, et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol2017; 24: 525–533.
4.
ToepferCNGarfinkelACVenturiniG, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation2020; 141: 828–842.
5.
GreenEMWakimotoHAndersonRL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science2016; 351: 617–621.
6.
Vander RoestASLiuCMorckMM, et al. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state. Proc Natl Acad Sci U S A2021; 118: e2025030118.
7.
AndersonRLTrivediDVSarkarSS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A2018; 115: E8143–E8152.
8.
DaySMTardiffJCOstapEM. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. J Clin Invest2022; 132: e148557.
9.
HeitnerSBJacobyDLesterSJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med2019; 170: 741–748.
10.
OlivottoIOreziakABarriales-VillaR, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2020; 396: 759–769.
11.
DesaiMYOwensAGeskeJB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol2022; 80: 95–108.
12.
SaberiSCardimNYamaniM, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation2021; 143: 606–608.
13.
MaronBJRowinEJMaronMS. Is regression of left ventricular hypertrophy really a good thing for patients with hypertrophic cardiomyopathy? The emerging mavacamten story. Am J Cardiol2021; 147: 145–146.
14.
ChuangCCollibeeSAshcraftL, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem2021; 64: 14142–14152.
15.
MalikFIRobertsonLAArmasDR, et al. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci2022; 7: 763–775.
16.
WasfyJHWaltonSMBeinfeldM, et al. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; Draft Evidence Report. Institute for Clinical and Economic Review, https://icer.org/hypertrophic-cardiomyopathy-2021/ (2021, accessed 16 October 2022).
17.
YoungMNKolteDCadiganME, et al. Multidisciplinary heart team approach for complex coronary artery disease: single center clinical presentation. J Am Heart Assoc2020; 9: e014738.
18.
BaumgartnerH. The 2017 ESC/EACTS guidelines on the management of valvular heart disease: what is new and what has changed compared to the 2012 guidelines?Wien Klin Wochenschr2018; 130: 168–171.
19.
LevineGNBatesERBlankenshipJC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol2011; 58: e44–e122.
20.
NeumannFJHochholzerWSiepeM. ESC/EACTS guidelines on myocardial revascularization 2018: the most important innovations [in German]. Herz2018; 43: 689–694.
